SE436740B - Forfarande for framstellning av derivat av 5-bensoyl-indan-2-karboxylsyra eller salter eller alkylestrar derav - Google Patents
Forfarande for framstellning av derivat av 5-bensoyl-indan-2-karboxylsyra eller salter eller alkylestrar deravInfo
- Publication number
- SE436740B SE436740B SE7714110A SE7714110A SE436740B SE 436740 B SE436740 B SE 436740B SE 7714110 A SE7714110 A SE 7714110A SE 7714110 A SE7714110 A SE 7714110A SE 436740 B SE436740 B SE 436740B
- Authority
- SE
- Sweden
- Prior art keywords
- indane
- formula
- benzoyl
- carboxylic acid
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- WOAAHXNXOSCQFP-UHFFFAOYSA-N 5-benzoyl-2,3-dihydro-1h-indene-2-carboxylic acid Chemical class C1=C2CC(C(=O)O)CC2=CC=C1C(=O)C1=CC=CC=C1 WOAAHXNXOSCQFP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- -1 5-substituted indane-2-carboxylic acids Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 150000001879 copper Chemical class 0.000 claims description 2
- 238000006193 diazotization reaction Methods 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LGTZRESQDNRCAZ-UHFFFAOYSA-N 1-benzoyl-2,3-dihydro-1H-indene-2-carboxylic acid Chemical compound C(C1=CC=CC=C1)(=O)C1C(CC2=CC=CC=C12)C(=O)O LGTZRESQDNRCAZ-UHFFFAOYSA-N 0.000 description 1
- GUAYTFRCWMRPCA-UHFFFAOYSA-N 5-(4-aminobenzoyl)-2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC(N)=CC=C1C(=O)C1=CC=C(CC(C2)C(O)=O)C2=C1 GUAYTFRCWMRPCA-UHFFFAOYSA-N 0.000 description 1
- MTGIUHYHWLXUHB-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C(CC(C2)C(O)=O)C2=C1 MTGIUHYHWLXUHB-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100020663 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ppm-1 gene Proteins 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SQNVFBHILRFQJY-UHFFFAOYSA-N n-(methylsulfamoyl)methanamine Chemical group CNS(=O)(=O)NC SQNVFBHILRFQJY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7637574A FR2374032A2 (fr) | 1976-12-14 | 1976-12-14 | Nouveaux acides carboxyliques derives de l'indane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7714110L SE7714110L (sv) | 1978-06-15 |
| SE436740B true SE436740B (sv) | 1985-01-21 |
Family
ID=9181028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7714110A SE436740B (sv) | 1976-12-14 | 1977-12-13 | Forfarande for framstellning av derivat av 5-bensoyl-indan-2-karboxylsyra eller salter eller alkylestrar derav |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS5373548A (de) |
| AT (1) | AT355559B (de) |
| AU (1) | AU515268B2 (de) |
| BE (1) | BE861826R (de) |
| CA (1) | CA1088554A (de) |
| CH (1) | CH627728A5 (de) |
| DD (1) | DD133323A6 (de) |
| DE (1) | DE2753315A1 (de) |
| DK (1) | DK144640C (de) |
| ES (1) | ES465056A2 (de) |
| FR (1) | FR2374032A2 (de) |
| GB (1) | GB1584298A (de) |
| HU (1) | HU177226B (de) |
| IE (1) | IE46013B1 (de) |
| IL (2) | IL60598A0 (de) |
| MX (1) | MX4954E (de) |
| NL (1) | NL7713876A (de) |
| NO (1) | NO774285L (de) |
| SE (1) | SE436740B (de) |
| SU (1) | SU799646A3 (de) |
| ZA (1) | ZA777438B (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2526124T3 (es) * | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | Agonistas del receptor GPR120 y sus usos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4980053A (de) * | 1972-12-05 | 1974-08-02 | ||
| JPS5838416B2 (ja) * | 1974-05-31 | 1983-08-23 | 武田薬品工業株式会社 | カンジヨウカゴウブツノセイゾウホウ |
| JPS5335944B2 (de) * | 1974-05-21 | 1978-09-29 |
-
1976
- 1976-12-14 FR FR7637574A patent/FR2374032A2/fr active Granted
-
1977
- 1977-11-30 DE DE19772753315 patent/DE2753315A1/de not_active Ceased
- 1977-12-12 GB GB51699/77A patent/GB1584298A/en not_active Expired
- 1977-12-13 SE SE7714110A patent/SE436740B/sv unknown
- 1977-12-13 DK DK554677A patent/DK144640C/da not_active IP Right Cessation
- 1977-12-13 IE IE2520/77A patent/IE46013B1/en unknown
- 1977-12-13 DD DD7700202588A patent/DD133323A6/de unknown
- 1977-12-13 HU HU77LI316A patent/HU177226B/hu unknown
- 1977-12-13 NO NO774285A patent/NO774285L/no unknown
- 1977-12-13 MX MX776686U patent/MX4954E/es unknown
- 1977-12-14 JP JP14943377A patent/JPS5373548A/ja active Pending
- 1977-12-14 CH CH1541077A patent/CH627728A5/fr not_active IP Right Cessation
- 1977-12-14 NL NL7713876A patent/NL7713876A/xx not_active Application Discontinuation
- 1977-12-14 BE BE183429A patent/BE861826R/xx not_active IP Right Cessation
- 1977-12-14 ZA ZA00777438A patent/ZA777438B/xx unknown
- 1977-12-14 AU AU31530/77A patent/AU515268B2/en not_active Expired
- 1977-12-14 CA CA293,076A patent/CA1088554A/fr not_active Expired
- 1977-12-14 AT AT892577A patent/AT355559B/de not_active IP Right Cessation
- 1977-12-14 ES ES465056A patent/ES465056A2/es not_active Expired
-
1979
- 1979-04-06 SU SU792746906A patent/SU799646A3/ru active
-
1980
- 1980-07-15 IL IL60598A patent/IL60598A0/xx unknown
- 1980-07-15 IL IL60599A patent/IL60599A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE46013L (en) | 1978-06-14 |
| JPS5373548A (en) | 1978-06-30 |
| GB1584298A (en) | 1981-02-11 |
| MX4954E (es) | 1983-01-13 |
| IE46013B1 (en) | 1983-01-26 |
| IL60599A0 (en) | 1980-09-16 |
| ZA777438B (en) | 1979-05-30 |
| BE861826R (fr) | 1978-06-14 |
| AU3153077A (en) | 1979-06-21 |
| ATA892577A (de) | 1979-08-15 |
| FR2374032B2 (de) | 1979-03-30 |
| SU799646A3 (ru) | 1981-01-23 |
| DK554677A (da) | 1978-06-15 |
| DK144640C (da) | 1982-10-04 |
| IL60598A0 (en) | 1980-09-16 |
| AU515268B2 (en) | 1981-03-26 |
| NO774285L (no) | 1978-06-15 |
| HU177226B (en) | 1981-08-28 |
| ES465056A2 (es) | 1979-01-16 |
| NL7713876A (nl) | 1978-06-16 |
| DD133323A6 (de) | 1978-12-27 |
| CH627728A5 (en) | 1982-01-29 |
| CA1088554A (fr) | 1980-10-28 |
| DK144640B (da) | 1982-04-26 |
| FR2374032A2 (fr) | 1978-07-13 |
| AT355559B (de) | 1980-03-10 |
| SE7714110L (sv) | 1978-06-15 |
| DE2753315A1 (de) | 1978-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4277497A (en) | Analgesic 2-(M-benzoylphenoxy)-propionic acid derivatives | |
| US3349088A (en) | Therapeutically valuable 1, 2-dihyro-1, 2, 4-benzotriazine derivatives and process for preparation thereof | |
| US4365076A (en) | Process for the preparation of cycloalkylidenemethylphenylacetic acid derivatives | |
| US3649679A (en) | Substituted phenylalkanoic acid derivatives ii | |
| US3639477A (en) | Novel propoxyguanidine compounds and means of producing the same | |
| US3624103A (en) | 3-indoleacetohydroxamic acids | |
| US3985777A (en) | Sulphamyl-benzoic acid derivatives | |
| US4011328A (en) | Derivatives of pyridine-3-acetic acid, process for their preparation and applications thereof | |
| US4350822A (en) | Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives | |
| US4539326A (en) | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents | |
| US3458633A (en) | Control of helminthiasis with a series of 2-(w-(2-thienyl)alkyl)-,2-(2-(2-thienyl)vinyl)-,and the corresponding isomeric 3-thienyl derivatives of thiazoline and 5,6-dihydro-4h-1,3-thiazine | |
| SE436740B (sv) | Forfarande for framstellning av derivat av 5-bensoyl-indan-2-karboxylsyra eller salter eller alkylestrar derav | |
| US3931286A (en) | Novel benzoylphenylacetic acid derivatives | |
| US3876683A (en) | (n-carboxymethyl)biphenyl acetamides | |
| US3590041A (en) | Novel halo-substituted cinnamic acid heterocyclic amides | |
| US3997589A (en) | 4-(2'-Fluoro-4-biphenylylr-4-oxo-butyric acid and esters and salts thereof | |
| US2861074A (en) | Substituted hydroxyergolenes | |
| US3270028A (en) | Certain 3-aryl-1, 2, 4-oxadiazoles | |
| US3557135A (en) | 2-beta-hydroxy ethylamino-4-5-diphenyl-oxazole | |
| US4136194A (en) | 2-phenyl-2-carboxyethyl 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetate and process for preparation thereof | |
| US4348403A (en) | 2-Amino-4-(4-benzyloxyphenyl)thiazoles, and their use in hyperlipemia | |
| US3678058A (en) | 1,3,4,9B-TETRAHYDRO-2(2H)-INDENO-{8 1,2-c{9 PYRIDINES | |
| SE447249B (sv) | Bensamidinderivat jemte terapeutisk komposition innefattande derivatet | |
| US3962303A (en) | Novel benzoylphenylacetic acid derivatives | |
| JPS6324498B2 (de) |